Impact of methotrexate and adalimumab on immune function of patients with psoriasis
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Accepted author manuscript, 1.99 MB, PDF document
Patients with psoriasis are commonly treated with methotrexate or biologics. We examined the immune response in a whole blood assay (TruCulture (R)) to assess the effect of methotrexate and adalimumab. Twenty patients with psoriasis were included and cytokine levels following stimulation with LPS, R848, HKCA, PolyIC, or a blank were investigated before and after 3-6 months of treatment with methotrexate or adalimumab and in patients who had received adalimumab >5 years. Methotrexate only induced minor changes in the cytokine responses, whereas adalimumab affected a wide range of cytokines important for the immune defense towards microorganisms. In the long-term adalimumab treated group, the cytokine levels were almost equivalent to the short-term adalimumab-treated group. Overall, methotrexate was not associated with cytokine suppression. Short and long-term treatment with adalimumab lowered multiple cytokines involved in the immune defense equally emphasizing the need to continuously be aware of the risk of infections in these patients.
Original language | English |
---|---|
Journal | Dermatologic Therapy |
Volume | 35 |
Issue number | 3 |
Number of pages | 8 |
ISSN | 1396-0296 |
DOIs | |
Publication status | Published - 2022 |
- adalimumab, immune response, methotrexate, microbiology, psoriasis, LONG-TERM SAFETY, RHEUMATOID-ARTHRITIS
Research areas
ID: 290042055